-
Medical journals
- Career
Gliptins: a safe and effective treatment of diabetes mellitus
Authors: Jiří Slíva 1,2; Martin Prázný 3
Authors‘ workplace: Farmakologický ústav 2. LF UK Praha, přednosta doc. MUDr. Martin Votava, Ph. D. 1; Ústav farmakologie 3. LF UK Praha, přednosta prof. MUDr. Jan Bultas, CSc. 2; III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA 3
Published in: Vnitř Lék 2014; 60(9): 772-774
Category:
Overview
Gliptins are well recognized substances modulating incretin system via inhibition of dipeptidylpeptidase IV. Their efficacy was demonstrated both in monotherapy and in combination with metformin, where they act synergistically. Hence, a better control of diabetes might be assumed. This short article aims to show current trends in their prescription in the Czech Republic.
Key words:
diabetes mellitus – dipeptidylpeptidase IV – gliptins – oral antidiabetics
Sources
1. Li L, Shen J, Bala MM et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014; 348: g2366. Dostupné z DOI: <http://doi: 10.1136/bmj.g2366>.
2. Egan AG, Blind E, Dunder K et al. Pancreatic safety of incretin-based drugs – FDA and EMA assessment. N Engl J Med 2014; 370(9): 794–797.
3. Panagoulias GS, Doupis J. Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination. Patient Prefer Adherence 2014; 8 : 227–236.
4. Koliaki C, Doupis J. Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology. Adv Ther 2012; 29(12): 993–1004.
5. Guarino E, Nigi L, Patti A et al. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opin Pharmacother 2012; 13(9): 1377–1384.
6. Benford M, Milligan G, Pike J et al. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther 2012; 29(1): 26–40.
Labels
Diabetology Endocrinology Internal medicine
Article was published inInternal Medicine
2014 Issue 9-
All articles in this issue
- Basal insulin glargine using a basal-bolus regimen in a common clinical practice: observational, non-interventional, multicenter, national project LINDA (Lantus in daily practice – safety and efficacy in basal bolus regimen)
- AGEs and RAGE – advanced glycation end-products and their receptor in questions and answers
- Liver, kidneys and diabetes: three faces of HNF1B gene deficit
- Problems of differential diagnosis of paraneoplastic hypoglycaemia
- Hypoglycemia as a limitation to the treatment of diabetes mellitus
- Changes of bone metabolism in diabetics
- Insulin resistance – its causes and therapy possibilities
- Glycemic variability and continuous monitoring of glycemia
- Life expectancy of people with type 1 diabetes in the past and today
- Gliptins: a safe and effective treatment of diabetes mellitus
- How we indicate oral antidiabetics today (from metformin to gliptins and gliflozins)
- Receptor pro konečné produkty pokročilé glykace (RAGE) – klíčový hráč diabetické angiopatie?
- Diabetes mellitus and pancreatic cancer – cause or result?
- Diabetes mellitus and pancreatic cancer – cause or result?
- Personalized therapy for diabetes in retrospect and prospect
- First fixed dose combination perindopril arginine-indapamide-amlodipine: new approach in combination therapy in hypertension
- Long-term acting insulin analogues and the risks of hypoglycemic incidence
- Factors causing damage and destruction of beta-cells of the islets of Langerhans in the pancreas
- Calcium, vitamin D and health
- SOLOSTAR study demonstrated high levels of patient satisfaction with the use of the insulin pen SoloStar® in the Czech Republic
- News and perspectives in insulin treatment
- Internal Medicine
- Journal archive
- Current issue
- Online only
- About the journal
Most read in this issue- Life expectancy of people with type 1 diabetes in the past and today
- Gliptins: a safe and effective treatment of diabetes mellitus
- Insulin resistance – its causes and therapy possibilities
- AGEs and RAGE – advanced glycation end-products and their receptor in questions and answers
Login#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Career